Identification of a critical sulfation in chondroitin that inhibits axonal regeneration.

Autor:	Pearson CS; Laboratory of Developmental Neurobiology, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, United States.; Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom., Mencio CP; Laboratory of Developmental Neurobiology, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, United States., Barber AC; Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom., Martin KR; Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom., Geller HM; Laboratory of Developmental Neurobiology, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, United States.
Jazyk:	angličtina
Zdroj:	ELife [Elife] 2018 May 15; Vol. 7. Date of Electronic Publication: 2018 May 15.
DOI:	10.7554/eLife.37139
Abstrakt:	The failure of mammalian CNS neurons to regenerate their axons derives from a combination of intrinsic deficits and extrinsic factors. Following injury, chondroitin sulfate proteoglycans (CSPGs) within the glial scar inhibit axonal regeneration, an action mediated by the sulfated glycosaminoglycan (GAG) chains of CSPGs, especially those with 4-sulfated (4S) sugars. Arylsulfatase B (ARSB) selectively cleaves 4S groups from the non-reducing ends of GAG chains without disrupting other, growth-permissive motifs. We demonstrate that ARSB is effective in reducing the inhibitory actions of CSPGs both in in vitro models of the glial scar and after optic nerve crush (ONC) in adult mice. ARSB is clinically approved for replacement therapy in patients with mucopolysaccharidosis VI and therefore represents an attractive candidate for translation to the human CNS. Competing Interests: CP, CM, AB, KM, HG No competing interests declared
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu